A new Covid-19 vaccine trial started on the first of March at San Gerardo (Monza, Italy): it’s an Italian vaccine designed by Takis and developed in partnership with Rottapharm Biotech.

Takis and Rottapharm Biotech are assessing the safety and immunogenicity of a plasmid-DNA vaccine on healthy adults volunteers. OPIS is the CRO in charge of the operational aspects of the clinical trial.

Phase I will enroll 80 healthy volunteers, assigned to four different groups, stratified to receive different doses; in Phase II, the number of participants will vary depending on the results obtained in Phase I.

Besides the University of Milano-Bicocca and San Gerardo hospital, the trial will be carried out at INMI Lazzaro Spallanzani in Rome and at Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples.

In this time of hardship caused by the pandemic, OPIS is deeply proud to contribute to developing an Italian, promising vaccine against Coronavirus.